Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733561 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
A Phase 1 study of Parkinson Disease, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03733561: Completed Phase 1 study of Parkinson Disease, sponsored by Luye Pharma Group.
NCT03733561 is a Phase 1 study of Parkinson Disease that has completed, run by Luye Pharma Group. The registered enrollment target is 40 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03733561, a Phase 1 study of Parkinson Disease, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers
Conditions Studied
Interventions
- DRUG LY03003
- DRUG Neupro 4Mg/24Hr Transdermal Patch
Study Locations (1)
Maryland
- Pharmaron CPC, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2018-12-23 |
| Phase | Phase 1 |
What the finished NCT03733561 record still lists
NCT03733561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which LY03003 is the first listed.
NCT03733561 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03733561 about?
NCT03733561 is a clinical study titled "A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro". Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers
What is the current status of trial NCT03733561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-11-09. Estimated completion is 2018-12-23.
What conditions does trial NCT03733561 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT03733561?
The interventions under investigation include: LY03003 (DRUG), Neupro 4Mg/24Hr Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT03733561?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03733561 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03733561's enrollment target sits among peer trials
40 173rd of 297 higher than 109 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI